Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.

Abstract: A device (100) for measuring ocular microtremor (OMT) of a patient's eye, comprises a light source (10) for illuminating a target area of the eye with a light beam. The device also comprises a detector (20) arranged to detect scattered light from the interaction of the light beam with the target area of the eye. The device further comprises a focusing lens (30) arranged to collect the scattered light for the detector, and a port in a wall of the device through which the light beam can exit the device and/or through which the scattered light can enter the device. The device is configured to stabilise and/or support the device on or against a patients head. A method of measuring microtremor of an eye is also provided.

Abstract: A robot is provided, the robot comprising a body carrying a first drive arrangement, a second drive arrangement and a stabiliser. The robot further comprises actuators operable to cause relative movement of the first drive arrangement, the second drive arrangement and the stabiliser, and to drive the first and the second drive arrangements. The robot is arrangeable in first, second and third configurations each having static stability. In the first configuration, the stabiliser and the first drive arrangement are arranged to contact the ground. In the second configuration, the stabiliser and the second drive arrangement are arranged to contact the ground. In the third configuration, the first and the second drive arrangements are arranged to contact the ground. No other ground contacting point is involved in conferring said static stability in said configurations.

Abstract: A heart valve therapeutic device (1) comprises a coaptation assist valve (20) comprising a conduit (2) with an outer surface (3) for coaption with the native leaflets, and a prosthetic flow valve (5) mounted within the conduit (2) to allow one-way flow through the conduit (2). Support for the coaptation assist valve (20) is provided by a support (10) for positioning the conduit (2) across the native leaflets, and connectors (15) attaching the conduit (2) to the support (10).

Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.

Abstract: The present invention relates to a method and compositions for the treatment of age-related macular degeneration (AMD), in particular dry-AMD, specifically geographic atrophy (GA) or advanced dry-AMD. Specifically, the invention relates to an inner-blood-retinal-barrier (iBRB) or blood-brain-barrier (BBB) tight junction protein and/or a circadian clock protein for use in the prevention and/or treatment of age-related macular degeneration.

Abstract: The invention provides a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis, using a molecule capable of acting as substrate for the queuine-insertase enzyme complex.

Abstract: A heart valve therapeutic device (1) comprises a coaptation assist valve (20) comprising a conduit (2) with an outer surface (3) for coaption with the native leaflets, and a prosthetic flow valve (5) mounted within the conduit (2) to allow one-way flow through the conduit (2). Support for the coaptation assist valve (20) is provided by a support (10) for positioning the conduit (2) across the native leaflets, and connectors (15) attaching the conduit (2) to the support (10).

Abstract: Compounds and pharmaceutical compositions for use in the treatment of psoriasis are disclosed. Preferred compounds have demonstrated efficacy in reducing skin scaling, erythema and skin thickness in the mouse model of Aldara-induced psoriasis.

Abstract: A homogenous composite material with increased tensile strength comprising 2-dimensional nano-sheets exfoliated from a 3-dimensional layered material mixed in a liquid non-Newtonian viscoelastic material to produce the homogenous composite material; and a process for making the same.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: The invention provides a method and system for Dynamic Bandwidth Assignment (DBA) Virtualization in a Passive Optical Network, comprising an Optical Line Termination (OLT) point and a plurality of Optical Network Units (ONU) and a plurality of Virtual Network Units (VNO), wherein each VNO is configured with a virtual Dynamic Bandwidth Assignment module to schedule a bandwidth assignment independently of the other VNOs and using a merging engine to implement a detailed bandwidth scheduling allocation over the Passive Optical Network.

Abstract: A heart valve therapeutic device (1) has an elongate anchor (7) wherein the anchor has a stiffness to hold its shape and location to support the valve element. The anchor may have a stylet or a shaped or stiff collar (70) arranged to provide a desired shape to the anchor (7) and it may be lockable. A prosthetic valve element (15) has leaflets (17) and is supported on the anchor by coupler (16, 50) at a desired location. There is an actuator for changing relative axial position of the proximal and distal couplers (16, 50) on the anchor. The anchor stiffness may be sufficient to provide sufficient support to resist axial forces from the ventricle in use without necessarily having a fixing element engaging heart tissue. The prosthetic leaflets (240) may extend proximally and radially outwardly, so that there is excellent co-apting of the native leaflets (NL) against the prosthetic leaflets (240).

Abstract: The present invention provides a method of using Raman spectroscopy for identification of low grade cervical cytology cases likely to progress to high grade/cancer. The Applicant has found that high quality Raman spectra can be successfully acquired from morphologically normal appearing cells from negative, LSIL and HSIL Thinprep® specimens and different grades of cervical pre-cancer can be separated with good sensitivities and specificities. Raman spectroscopy can further identify different categories of the LSIL cases i.e., whether they are likely to regress to negative or progress to HSIL cytology.

Abstract: A heart valve therapeutic device (1) comprises a coaptation assist valve (20) comprising a conduit (2) with an outer surface (3) for coaption with the native leaflets, and a prosthetic flow valve (5) mounted within the conduit (2) to allow one-way flow through the conduit (2). Support for the coaptation assist valve (20) is provided by a support (10) for positioning the conduit (2) across the native leaflets, and connectors (15) attaching the conduit (2) to the support (10).

Abstract: The present invention relates to a method and system energy aware scheduling for sensors (Internet of Things (IoT)). More specifically, the method and system relates to energy scheduling of battery powered sensors or sensors powered using energy harvesters such that accurate and up to date information may be received from said sensors and at the same time minimizing the power utilized by said battery powered or energy harvester powered sensors.

Abstract: A heart valve therapeutic device (1) has an elongate anchor (7) wherein the anchor has a stiffness to hold its shape and location to support the valve element. The anchor may have a stylet or a shaped or stiff collar (70) arranged to provide a desired shape to the anchor (7) and it may be lockable. A prosthetic valve element (15) has leaflets (17) and is supported on the anchor by coupler (16, 50) at a desired location. There is an actuator for changing relative axial position of the proximal and distal couplers (16, 50) on the anchor. The anchor stiffness may be sufficient to provide sufficient support to resist axial forces from the ventricle in use without necessarily having a fixing element engaging heart tissue. The prosthetic leaflets (240) may extend proximally and radially outwardly, so that there is excellent co-apting of the native leaflets (NL) against the prosthetic leaflets (240).

Abstract: The invention provides a method and system for Dynamic Bandwidth Assignment (DBA) Virtualization in a Passive Optical Network, comprising an Optical Line Termination (OLT) point and a plurality of Optical Network Units (ONU) and a plurality of Virtual Network Units (VNO), wherein each VNO is configured with a virtual Dynamic Bandwidth Assignment module to schedule a bandwidth assignment independently of the other VNOs and using a merging engine to implement a detailed bandwidth scheduling allocation over the Passive Optical Network.

Abstract: A heart valve therapeutic device (1) comprises a coaptation assist valve (20) comprising a conduit (2) with an outer surface (3) for coaption with the native leaflets, and a prosthetic flow valve (5) mounted within the conduit (2) to allow one-way flow through the conduit (2). Support for the coaptation assist valve (20) is provided by a support (10) for positioning the conduit (2) across the native leaflets, and connectors (15) attaching the conduit (2) to the support (10).

Abstract: A polymerizable boronic acid salt has the general structure (I): A+.X? (I) in which: A represents a quaternised ammonium boronic acid cation; and X represents an anion, wherein either A or X contains a free-radical polymerizable group. Diol-sensing hydrogels comprising a crosslinked polymeric matrix formed from the polymerizable boronic acid salt monomer are also described.